Chapter 19 Estrogen in Systemic Lupus Erythematosus: Lessons from the SELENA Study

Sangeeta D. Sule; Michelle Petri

doi:10.1016/S1571-5078(07)00219-X

Chapter 19 Estrogen in Systemic Lupus Erythematosus: Lessons from the SELENA Study

Sangeeta D. Sule, Michelle Petri

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

There is a strong female predominance in SLE, implicating estrogens in the pathogenesis of disease. However, recent studies have shown that exogenous estrogens, given as oral contraceptives or HRT, do not increase the risk of mild or moderate flares in women with SLE. These and other studies provide physicians with new evidence for the rational use of estrogen therapy in women with SLE. {A textbox is presented}.

Original language	English (US)
Title of host publication	Endocrine Manifestations of Systemic Autoimmune Diseases
Editors	Sara Walker, Luis Jara
Pages	223-227
Number of pages	5
DOIs	https://doi.org/10.1016/S1571-5078(07)00219-X
State	Published - Dec 1 2008

Publication series

Name	Handbook of Systemic Autoimmune Diseases
Volume	9
ISSN (Print)	1571-5078

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Immunology and Allergy
Immunology

Access to Document

10.1016/S1571-5078(07)00219-X

Fingerprint Dive into the research topics of 'Chapter 19 Estrogen in Systemic Lupus Erythematosus: Lessons from the SELENA Study'. Together they form a unique fingerprint.

Cite this

@inbook{7edd0f0e4eba425c9b21fd1ec1b23e2a,

title = "Chapter 19 Estrogen in Systemic Lupus Erythematosus: Lessons from the SELENA Study",

abstract = "There is a strong female predominance in SLE, implicating estrogens in the pathogenesis of disease. However, recent studies have shown that exogenous estrogens, given as oral contraceptives or HRT, do not increase the risk of mild or moderate flares in women with SLE. These and other studies provide physicians with new evidence for the rational use of estrogen therapy in women with SLE. {A textbox is presented}.",

author = "Sule, {Sangeeta D.} and Michelle Petri",

year = "2008",

month = dec,

day = "1",

doi = "10.1016/S1571-5078(07)00219-X",

language = "English (US)",

isbn = "9780444531728",

series = "Handbook of Systemic Autoimmune Diseases",

pages = "223--227",

editor = "Sara Walker and Luis Jara",

booktitle = "Endocrine Manifestations of Systemic Autoimmune Diseases",

}

TY - CHAP

T1 - Chapter 19 Estrogen in Systemic Lupus Erythematosus

T2 - Lessons from the SELENA Study

AU - Sule, Sangeeta D.

AU - Petri, Michelle

PY - 2008/12/1

Y1 - 2008/12/1

N2 - There is a strong female predominance in SLE, implicating estrogens in the pathogenesis of disease. However, recent studies have shown that exogenous estrogens, given as oral contraceptives or HRT, do not increase the risk of mild or moderate flares in women with SLE. These and other studies provide physicians with new evidence for the rational use of estrogen therapy in women with SLE. {A textbox is presented}.

AB - There is a strong female predominance in SLE, implicating estrogens in the pathogenesis of disease. However, recent studies have shown that exogenous estrogens, given as oral contraceptives or HRT, do not increase the risk of mild or moderate flares in women with SLE. These and other studies provide physicians with new evidence for the rational use of estrogen therapy in women with SLE. {A textbox is presented}.

UR - http://www.scopus.com/inward/record.url?scp=67649663691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649663691&partnerID=8YFLogxK

U2 - 10.1016/S1571-5078(07)00219-X

DO - 10.1016/S1571-5078(07)00219-X

M3 - Chapter

AN - SCOPUS:67649663691

SN - 9780444531728

T3 - Handbook of Systemic Autoimmune Diseases

SP - 223

EP - 227

BT - Endocrine Manifestations of Systemic Autoimmune Diseases

A2 - Walker, Sara

A2 - Jara, Luis

ER -